Elevated Cell-Free DNA Measured by a Simple Assay Is Associated With Increased Rate of Colorectal Cancer Relapse

Am J Clin Pathol. 2016 Jun;145(6):852-7. doi: 10.1093/ajcp/aqw068. Epub 2016 Jun 6.

Abstract

Objectives: For patients with early stage colorectal cancer (CRC), markers of high-risk relapse are needed. In a previous study on 38 randomly selected patients with CRC, we found good correlation between presurgery cell-free DNA (CFD) concentrations and standard prognostic factors. In the current study, we revisited the same patients at 5-year survival, aiming to evaluate the predictive power of presurgery CFD levels.

Methods: We revisited 38 patients with CRC previously analyzed for 5-year outcome. CFD was measured using a simple fluorescent assay that we developed.

Results: All recurrent patients and patients who had died of cancer within 5 years were shown to have presurgery CFD values above 800 ng/mL. The negative predictive value for cancer-related disease was 100%. Cox regression analysis for disease-free survival showed a hazard ratio of 6.03 (P = .003) for CFD, which was higher than the ratio of the disease stage, 1.9 (P = .006). The survival-free curve of stage I and II patients with elevated CFD was significantly different from patients with normal levels (P = .0136); 5 (41.7%) of 12 patients had died of cancer or had experienced a recurrence.

Conclusions: CFD may possibly be a decisive criterion to identify patients with local disease who might benefit from adjuvant chemotherapy.

Keywords: Biomarkers; Circulating cell-free DNA (CFD); Colorectal cancer (CRC); Hazard ratio; Prognosis; Treatment decisive marker.

MeSH terms

  • Aged
  • Biomarkers, Tumor / blood*
  • Colorectal Neoplasms / blood*
  • Colorectal Neoplasms / mortality
  • Colorectal Neoplasms / pathology
  • DNA / blood*
  • Disease-Free Survival
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / blood*
  • Neoplasm Recurrence, Local / mortality
  • Proportional Hazards Models
  • Sensitivity and Specificity

Substances

  • Biomarkers, Tumor
  • DNA